Swiss National Bank’s AbbVie ABBV Stock Holding History

Swiss National Bank’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.13B	Buy	5,186,810 +346,000	+7%	+$76.8M	0.65%	20
2025 Q4	$1.11B	Sell	4,840,810 -251,000	-5%	-$57.2M	0.66%	18
2025 Q3	$1.18B	Sell	5,091,810 -263,000	-5%	-$53.6M	0.68%	21
2025 Q2	$994M	Buy	5,354,810 +370,800	+7%	+$68.9M	0.6%	22
2025 Q1	$1.04B	Sell	4,984,010 -5,800	-0.1%	-$1.13M	0.74%	21
2024 Q4	$887M	Sell	4,989,810 -251,100	-5%	-$46.2M	0.59%	23
2024 Q3	$1.03B	Sell	5,240,910 -1,600	-0%	-$299K	0.67%	21
2024 Q2	$899M	Sell	5,242,510 -44,800	-0.8%	-$7.42M	0.62%	21
2024 Q1	$963M	Sell	5,287,310 -231,900	-4%	-$40M	0.67%	21
2023 Q4	$855M	Sell	5,519,210 -155,600	-3%	-$22.7M	0.63%	21
2023 Q3	$846M	Sell	5,674,810 -696,600	-11%	-$102M	0.66%	20
2023 Q2	$858M	Sell	6,371,410 -647,000	-9%	-$94.9M	0.58%	24
2023 Q1	$1.12B	Sell	7,018,410 -167,600	-2%	-$25.6M	0.77%	17
2022 Q4	$1.16B	Sell	7,186,010 -472,365	-6%	-$72.4M	0.83%	18
2022 Q3	$1.03B	Sell	7,658,375 -14,300	-0.2%	-$2.05M	0.74%	19
2022 Q2	$1.18B	Buy	7,672,675 +15,500	+0.2%	+$2.37M	0.8%	18
2022 Q1	$1.24B	Buy	7,657,175 +940,300	+14%	+$137M	0.7%	18
2021 Q4	$909M	Sell	6,716,875 -266,900	-4%	-$31.5M	0.55%	29
2021 Q3	$753M	Sell	6,983,775 -216,800	-3%	-$24.8M	0.48%	37
2021 Q2	$811M	Buy	7,200,575 +410,984	+6%	+$46.3M	0.5%	32
2021 Q1	$735M	Buy	6,789,591 +125,400	+2%	+$13.4M	0.49%	36
2020 Q4	$714M	Sell	6,664,191 -210,700	-3%	-$20.2M	0.51%	34
2020 Q3	$602M	Sell	6,874,891 -110,400	-2%	-$10.4M	0.47%	40
2020 Q2	$686M	Buy	6,985,291 +1,245,930	+22%	+$110M	0.58%	30
2020 Q1	$437M	Buy	5,739,361 +1,077,400	+23%	+$91.8M	0.46%	43
2019 Q4	$413M	Sell	4,661,961 -220,100	-5%	-$18.3M	0.42%	42
2019 Q3	$370M	Buy	4,882,061 +73,232	+2%	+$5.02M	0.39%	50
2019 Q2	$350M	Sell	4,808,829 -212,200	-4%	-$16.7M	0.38%	50
2019 Q1	$405M	Buy	5,021,029 +98,400	+2%	+$8.05M	0.44%	43
2018 Q4	$454M	Buy	4,922,629 +81,400	+2%	+$7.16M	0.58%	28
2018 Q3	$458M	Sell	4,841,229 -209,000	-4%	-$19.8M	0.51%	34
2018 Q2	$468M	Sell	5,050,229 -71,700	-1%	-$7M	0.54%	30
2018 Q1	$485M	Sell	5,121,929 -758,100	-13%	-$83.3M	0.59%	29
2017 Q4	$569M	Buy	5,880,029 +9,700	+0.2%	+$914K	0.61%	30
2017 Q3	$522M	Buy	5,870,329 +46,500	+0.8%	+$3.54M	0.59%	32
2017 Q2	$422M	Buy	5,823,829 +65,600	+1%	+$4.41M	0.5%	35
2017 Q1	$375M	Buy	5,758,229 +1,222,400	+27%	+$76.9M	0.47%	36
2016 Q4	$284M	Buy	4,535,829 +50,100	+1%	+$3.06M	0.45%	38
2016 Q3	$283M	Sell	4,485,729 -30,500	-0.7%	-$1.97M	0.45%	37
2016 Q2	$280M	Buy	4,516,229 +269,100	+6%	+$16.4M	0.45%	38
2016 Q1	$233M	Buy	4,247,129 +1,239,800	+41%	+$69.1M	0.43%	42
2015 Q4	$178M	Sell	3,007,329 -62,200	-2%	-$3.58M	0.43%	41
2015 Q3	$167M	Buy	3,069,529 +287,200	+10%	+$18.7M	0.43%	42
2015 Q2	$187M	Buy	2,782,329 +355,211	+15%	+$23.2M	0.48%	36
2015 Q1	$142M	Buy	2,427,118 +947,300	+64%	+$57.2M	0.38%	53
2014 Q4	$96.8M	Sell	1,479,818 -44,000	-3%	-$2.77M	0.36%	58
2014 Q3	$88M	Sell	1,523,818 -24,400	-2%	-$1.35M	0.34%	61
2014 Q2	$87.4M	Buy	1,548,218 +6,200	+0.4%	+$325K	0.32%	63
2014 Q1	$79.3M	Sell	1,542,018 -147,400	-9%	-$7.45M	0.31%	71
2013 Q4	$89.2M	Sell	1,689,418 -25,600	-1%	-$1.26M	0.35%	64
2013 Q3	$76.7M	Buy	1,715,018 +32,900	+2%	+$1.46M	0.32%	67
2013 Q2	$69.5M	Buy	+1,682,118	New	+$73.6M	0.31%	70

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Swiss National Bank's ABBV Position: Q1 2026 in Review

Swiss National Bank increased its AbbVie (ABBV) stake by 7.1% in Q1 2026, buying an estimated $76.8M and bringing the position to 5,186,810 shares worth $1.13B. The position accounts for 0.65% of the portfolio, ranked #20.

Swiss National Bank first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $1.24B in Q1 2022. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Swiss National Bank held 5,186,810 shares of AbbVie worth $1.13B as of Q1 2026.
Swiss National Bank bought 346,000 AbbVie shares in Q1 2026, an estimated $76.8M.
AbbVie made up 0.65% of Swiss National Bank's portfolio in Q1 2026, its #20 holding.
Swiss National Bank first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
Swiss National Bank's AbbVie position peaked at $1.24B in Q1 2022.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.